SWOG clinical trial number
S1609

DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors

98% Accrual
Accrual
98%
Open
Phase
98% Accrual
Accrual
98%
Abbreviated Title
DART
Status Notes
Permanently Closed to Accrual: 1, 2, 3,4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53.

Temporarily Closed to Accrual: 40, 46.

For the PD-L1 amplified cohort, patients do NOT need to qualify under one of the applicable histologies listed in Section 18.1.

Patients may now be registered directly to S1609 without having to be enrolled on EAY131 ("NCI-MATCH"). See Revision #3 for details.


Activated
01/13/2017
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Early Therapeutics & Rare Cancers
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Lung Cancer
Melanoma

Treatment

Ipilimumab Nivolumab

Other Clinical Trials

S2206
SWOG Clinical Trial Number

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer

Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
17% Accrual
Accrual
17%
Open
Phase
S2212
SWOG Clinical Trial Number

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)

Research Committee(s)
Breast Cancer
Activated
07/21/2023
25% Accrual
Accrual
25%
Open
Phase
CTSU/NRG-BR007
SWOG Clinical Trial Number

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer

Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase